Carbosynth specialises in custom synthesis and product development, which first led Carbosynth into the enzyme substrate arena. In 2008 a range of lysosomal storage disorder (LSD) substrates was introduced and over the last decade this range was expanded to meet industry demands. We are now pleased to offer Moscerdam's novel substrates for lysosomal enzymes for robust, fluorogenic assays.
Moscerdam has been the pioneer for the last 15 years in providing novel substrates for lysosomal enzymes that can be used in fluorogenic assays for the diagnosis of LSDs. LSDs are a group of about 50 rare inherited metabolic disorders that result from defects in lysosomal function. LSDs occur with incidences of about 1:5,000 - 10,000 in the general population. The lysosome is commonly referred to as the cell's recycling centre because it processes unwanted material into substances that the cell can use. Lysosomes break down this unwanted matter by using enzymes. LSDs are usually triggered when an enzyme in the process exists in too small an amount or is missing altogether. The symptoms of LSD vary, and can include developmental delay, movement disorders, seizures, dementia, deafness, or blindness. The majority of patients are initially screened by enzyme assay, which is the most efficient method to arrive at a definitive diagnosis.
The addition of Moscerdam substrates will further enhance Carbosynth’s enzyme substrate portfolio and strengthen our position as a leading supplier of diagnostic reagents. Carbosynth will continue to supply the high purity products this community have come to expect.
Dr Vanessa Eastwick-Field, Managing Director of Carbosynth said:
“We have worked with Otto in this field for a number of years and are excited about this agreement. The acquisition of the assets of Moscerdam will strengthen our position with lysosomal storage disorder substrates, and also aligns with our strategy to continue build a leading Life Science businesss”.
Dr Otto van Diggelen CEO of Moscerdam said:
“I have been involved in the field of LSD for much of my professional life and Moscerdam was established to provide robust diagnostics for this important area of healthcare. As I am now retired, this agreement ensures the continued supply of the Moscerdam range and I am looking forward to working with Carbosynth during this transition period”.
All enquiries regarding Moscerdam substrates can now be referred directly to Carbosynth at firstname.lastname@example.org.